Grifols is collaborating in several clinical trials in U.S Y Spain with the aim of developing a potential Covid-19 treatment, as reported by the group in a statement sent to the National Securities Market Commission (CNMV).
According to the Catalan firm, it would be the first treatment to specifically combat the new coronavirus, and that the pact includes the development of preclinical and clinical studies necessary to determine the efficacy of anti-SARS-CoV-2 hyperimmune immunoglobulin therapy to treat COVID-19.
The company has indicated that in the United States it is collaborating with various state agencies, such as the Food and Drug Administration (FDA) to collect plasma from patients who have overcome the disease, process it and produce immunoglobulins anti-Covid-19.
On the other hand, Grifols is working in Spain on a clinical trial with recovered patient plasma inactivated by methylene blue and collaborates with certain donation centers and public hospitals. It is also collaborating with some hospital centers in the design of various clinical studies to verify the efficacy and potential use of some drugs against the Covid-19.
Grifols added that he is working on the development of a diagnostic method of the coronavirus, with the capacity to process 1,000 samples daily and that “could be available in the coming weeks”.